Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2024-02-08 4:36 pm Purchase | 13G | SPYRE THERAPEUTICS, INC SYRE | INTEGRATED CORE STRATEGIES (US) LLC | 108,486 0.3% | 108,486 (New Position) | View |
| 2023-12-29 5:00 pm Sale | 13D | SPYRE THERAPEUTICS, INC SYRE | Fairmount Funds Management LLC | 836,459 2.32% | -2,977,442 (-78.07%) | View |
| 2023-12-13 3:50 pm Purchase | 13G | SPYRE THERAPEUTICS, INC SYRE | PERCEPTIVE ADVISORS LLC | 2,606,679 7.2% | 2,606,679 (New Position) | View |
| 2023-12-11 5:21 pm Unchanged | 13D | SPYRE THERAPEUTICS, INC SYRE | Fairmount Funds Management LLC | 3,813,901 10.59% | 0 (Unchanged) | View |
| 2023-12-01 4:15 pm Purchase | 13G | SPYRE THERAPEUTICS, INC SYRE | COMMODORE CAPITAL LP | 1,834,084 6.1% | 1,834,084 (New Position) | View |
| 2023-11-29 5:08 pm Purchase | 13D | SPYRE THERAPEUTICS, INC SYRE | Fairmount Funds Management LLC | 3,813,901 12.7% | 3,813,901 (New Position) | View |
| 2023-11-14 3:13 pm Purchase | 13G | AEGLEA BIOTHERAPEUTICS, INC. C AGLE | Deutsch Peter E. | 383,659 9.48% | 383,659 (New Position) | View |
| 2023-07-28 09:01 am Purchase | 13G | AEGLEA BIOTHERAPEUTICS, INC. C AGLE | Polar Capital Holdings Plc | 3,936,198 5.02% | 3,936,198 (New Position) | View |
| 2023-07-18 4:01 pm Purchase | 13G | AEGLEA BIOTHERAPEUTICS, INC. C AGLE | Logos Global Management LP | 6,350,000 8.1% | 6,350,000 (New Position) | View |
| 2023-07-10 4:16 pm Purchase | 13G | AEGLEA BIOTHERAPEUTICS, INC. C AGLE | Venrock Healthcare Capital Partners III L.P. | 7,980,000 9.99% | 7,980,000 (New Position) | View |
| 2023-07-03 4:20 pm Purchase | 13G | AEGLEA BIOTHERAPEUTICS, INC. C AGLE | Affinity Asset Advisors LLC | 7,477,000 9.23% | 7,477,000 (New Position) | View |
| 2023-06-30 5:24 pm Purchase | 13D | AEGLEA BIOTHERAPEUTICS, INC. C AGLE | Fairmount Funds Management LLC | 19,590,000 19.99% | 19,590,000 (New Position) | View |
| 2023-06-30 4:20 pm Purchase | 13G | AEGLEA BIOTHERAPEUTICS, INC. C AGLE | EcoR1 Capital Fund Qualified L.P. | 5,000,000 6.4% | 5,000,000 (New Position) | View |
| 2023-06-30 4:00 pm Purchase | 13G | AEGLEA BIOTHERAPEUTICS, INC. C AGLE | Deep Track Capital LP | 7,258,056 9.99% | 7,258,056 (New Position) | View |
| 2023-02-14 4:55 pm Purchase | 13G | AEGLEA BIOTHERAPEUTICS, INC. C AGLE | Nantahala Capital Management LLC | 4,611,302 7.5% | 1,797,742 (+63.90%) | View |
| 2023-02-14 4:01 pm Sale | 13G | AEGLEA BIOTHERAPEUTICS, INC. C AGLE | ORBIMED ADVISORS LLC | 1,797,221 2.9% | -2,158,903 (-54.57%) | View |
| 2023-02-14 4:00 pm Purchase | 13G | AEGLEA BIOTHERAPEUTICS, INC. C AGLE | BAKER BROS. ADVISORS LP | 6,384,013 9.9% | 1,339,535 (+26.55%) | View |
| 2023-02-14 2:51 pm Purchase | 13G | AEGLEA BIOTHERAPEUTICS, INC. C AGLE | Rock Springs Capital Management LP | 3,413,906 5.55% | 3,413,906 (New Position) | View |
| 2023-02-14 06:04 am Purchase | 13G | AEGLEA BIOTHERAPEUTICS, INC. C AGLE | BCLS II Equity Opportunities LP | 5,347,689 8.7% | 2,500,000 (+87.79%) | View |
| 2023-02-13 08:41 am Purchase | 13G | AEGLEA BIOTHERAPEUTICS, INC. C AGLE | SUVRETTA CAPITAL MANAGEMENT LLC | 6,376,373 9.99% | 3,805,373 (+148.01%) | View |